Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide versus placebo in Gallium-68 DOTATATE PET-positive non-functioning pituitary macroadenoma
NL-OMON50502Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in Pituitary macroadenoma comparing Lanreotide with Placebo (2 arms). Primary endpoint: Change in cranio-caudal NFMA size. Started Nov 2015; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
Pituitary macroadenoma
Beyond the preview
Go deeper on NL-OMON50502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50502.